Non-Small Cell Lung Cancer (NSCLC):

CIRB #H-33418/CTSU #A151216 (ALCHEMIST): Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

ALCHEMIST A151216 Sub-studies:

CIRB #H-33430/CTSU #A081105: Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (NSCLC)

CIRB #H-33425/CTSU #E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein 

CIRB #H-36723/ NRG #LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

IRB #H-38204/ Merck #MK3475-671 (KEYNOTE 671): A Phase III, Randomized, Double Blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA NSCLC

Small Cell Lung Cancer (SCLC):

HIRB #H-38781/ TARVEDA #PEN-221:  A Phase 1/2a, open label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing advanced cancers, including gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of lung